Soleno Therapeutics (SLNO) Cost of Revenue (2016 - 2017)
Historic Cost of Revenue for Soleno Therapeutics (SLNO) over the last 4 years, with Q2 2017 value amounting to $42000.0.
- Soleno Therapeutics' Cost of Revenue fell 7454.55% to $42000.0 in Q2 2017 from the same period last year, while for Dec 2017 it was $69000.0, marking a year-over-year decrease of 9018.49%. This contributed to the annual value of $26000.0 for FY2017, which is N/A changed from last year.
- Latest data reveals that Soleno Therapeutics reported Cost of Revenue of $42000.0 as of Q2 2017, which was down 7454.55% from $27000.0 recorded in Q1 2017.
- Soleno Therapeutics' Cost of Revenue's 5-year high stood at $538000.0 during Q1 2016, with a 5-year trough of $12000.0 in Q2 2014.
- Moreover, its 4-year median value for Cost of Revenue was $165000.0 (2016), whereas its average is $250529.9.
- Its Cost of Revenue has fluctuated over the past 5 years, first soared by 411666.67% in 2015, then tumbled by 9498.14% in 2017.
- Over the past 4 years, Soleno Therapeutics' Cost of Revenue (Quarter) stood at $156359.0 in 2014, then surged by 218.8% to $498470.0 in 2015, then tumbled by 66.9% to $165000.0 in 2016, then crashed by 74.55% to $42000.0 in 2017.
- Its Cost of Revenue was $42000.0 in Q2 2017, compared to $27000.0 in Q1 2017 and $165000.0 in Q2 2016.